WuXi AppTec (OTCMKTS:WUXAY – Get Free Report) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday, Zacks reports.
WuXi AppTec Stock Up 1.8%
Shares of WUXAY stock opened at $27.67 on Monday. The company has a 50-day simple moving average of $25.10 and a 200 day simple moving average of $19.86. WuXi AppTec has a 52 week low of $12.45 and a 52 week high of $27.80.
WuXi AppTec Company Profile
WuXi AppTec is a contract research, development and manufacturing organization (CRDMO) that provides services to pharmaceutical, biotechnology and medical-device companies. Its offerings span the drug-development process, including early-stage discovery, medicinal and synthetic chemistry, biology research, analytical testing, preclinical studies, clinical research support, process development and commercial manufacturing.
The company supports a broad range of therapeutic programs, with capabilities covering small-molecule drugs, biologics, chemical and pharmaceutical products, and cell and gene therapies.
Further Reading
- Five stocks we like better than WuXi AppTec
- Rivian Escapes the EV Graveyard—But Can It Stay Alive?
- Allient’s Data Center and Defense Momentum Is Raising the Stakes
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
Receive News & Ratings for WuXi AppTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi AppTec and related companies with MarketBeat.com's FREE daily email newsletter.
